BioCentury
ARTICLE | Company News

MiaMed, Amicus Therapeutics deal

July 25, 2016 7:00 AM UTC

Amicus acquired neurology company MiaMed and its preclinical program for cyclin-dependent kinase-like 5 deficiency. MiaMed received $6.5 million up front in cash and stock and is eligible for up to $1...